Mitsubishi Tanabe unveils new oral MS candidate
This article was originally published in Scrip
Executive Summary
Japan's Mitsubishi Tanabe Pharma (MTP) has begun the early clinical development in Europe of MT-1303, a follow on to its first-in-class oral multiple sclerosis drug fingolimod.